Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line treatment for advanced or unresectable biliary tract cancer
MOH_2019-07-23_007297Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Pembrolizumab + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on MOH_2019-07-23_007297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-23_007297.